Table 1

Baseline characteristics of patients with and without 1-year MRI erosive progression, and associations between baseline characteristics and MRI erosive progression (univariate logistic regression analyses)

Comparison of patients with and without MRI erosive progression*Univariate logistic regression analyses
VariablesMRI erosive progression (n=53)No MRI erosive progression (n=26)p ValueOR (95% CI)p Value
Demographic variables
 Female38 (71.7)23 (88.5)0.103.03 (0.79 to 11.60)0.11
 Age, years57.5 (48.7–65.1)58.7 (44.9–68.2)0.811.00 (0.97 to 1.03)0.91
 Disease duration, days112.0 (70.0–190.0)91.5 (61.8–192.5)0.681.00 (1.00 to 1.01)0.79
Measures of disease severity
 ESR, mm/h15.0 (7.5–25.0)12.0 (9.8–22.0)0.731.02 (0.98 to 1.06)0.29
 CRP, mg/l5.2 (2.1–12.3)4.4 (1.9–7.6)0.251.04 (0.98 to 1.10)0.16
 Anti-CCP positive, >25 U/ml31 (58.5)13 (50.0)0.591.30 (0.50 to 3.38)0.59
 IgM RF positive, >25 U/ml26 (49.1)10 (38.5)0.451.44 (0.55 to 3.79)0.45
 DAS284.4 (3.0–5.4)4.0 (3.3–4.9)0.481.15 (0.80 to 1.64)0.46
Imaging modalities
 MRI synovitis5.0 (4.0–6.0)4.0 (3.0–6.0)0.091.24 (0.97 to 1.57)0.08
 MRI BME3.0 (1.3–7.0)2.0 (1.0–3.0)0.051.24 (1.02 to 1.51)0.03
 MRI tenosynovitis8.0 (6.0–11.0)9.0 (6.0–11.0)0.630.97 (0.85 to 1.11)0.66
 USGS inflammation1.0 (1.0–2.0)0.5 (0.0–1.0)0.0032.15 (1.23 to 3.75)0.01
 DXR BMD, g/m20.567 (0.506–0.631)0.596 (0.502–0.609)0.903.41 (0.01 to 1058.6)0.68
 DXR BMD, 3-month change, %−0.4 (−1.3–0.1)−0.1 (−1.0–0.8)0.100.70 (0.44 to 1.13)0.15
 Radiographic damage, vdHSS2.0 (0.0–6.0)2.0 (0.0–4.0)0.711.05 (0.94 to 1.17)0.43
  • * Median (IQR) for continuous variables, number (%) for counts. Comparison of independent groups by Mann–Whitney U test or χ2 tests.

  • Dependent variable; MRI erosive progression versus no progression.

  • p Value ≤0.05.

  • Anti-CCP, antibody to cyclic citrullinated protein; BME, bone marrow oedema; CRP, C-reactive protein; DAS28, disease activity score based on 28 joint count; DXR BMD, digital x-ray radiogrammetry bone mineral density; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor; USGS, ultrasound grey-scale; vdHSS, van der Heijde Sharp score.